How CTF is trying to rescue pharma’s shelved rare disease drugs

Right now, more than 5,000 potential rare disease treatments are sitting on drug company shelves, according to Children’s Tumor Foundation (CTF) CEO Annette Bakker. That includes drug candidates that companies have stopped actively developing, often after substantial preclinical, toxicology or early clinical work. Nonprofit organizations can help close the gap. One example is the Children’s… The post How CTF is trying to rescue pharma’s shelved rare disease drugs appeared first on Drug Discovery and Development.

Continue reading →